Sodium nitrite inhalation - Savara Pharmaceuticals
Alternative Names: AIR-001; AironiteLatest Information Update: 20 May 2022
At a glance
- Originator National Heart, Lung and Blood Institute
- Developer Aires Pharmaceuticals; Mayo Clinic; Savara Pharmaceuticals; University of Pittsburgh
- Class Antidotes; Antihypertensives; Antivirals; Nitrites; Small molecules; Sodium compounds; Vascular disorder therapies; Vasodilators
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heart failure; Pseudomonal infections; Pulmonary arterial hypertension; Pulmonary hypertension
Most Recent Events
- 12 Apr 2022 Mayo Clinic in collaboration with Aires Pharmaceuticals, Mast Therapeutics and National Heart, Lung, and Blood Institute completes a phase II trial for Heart Failure in USA (NCT02713126)
- 11 Mar 2018 Discontinued - Phase-I/II for Pseudomonal infections in USA (Inhalation)
- 11 Mar 2018 Discontinued - Phase-II for Heart failure in USA (Inhalation)